Influenza virus vaccine - Japan Vaccine/Terumo
Alternative Names: VN 100 - Japan Vaccine/TerumoLatest Information Update: 02 Oct 2021
At a glance
- Originator Daiichi Sankyo Company; Japan Vaccine; Kitasato Daiichi Sankyo Vaccine; Terumo
 - Developer Daiichi Sankyo Biotech; Daiichi Sankyo Company; Japan Vaccine; Terumo
 - Class Influenza virus vaccines; Vaccines
 - Mechanism of Action Immunostimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Discontinued Influenza virus infections
 
Most Recent Events
- 31 Oct 2018 Discontinued - Phase-III for Influenza virus infections (In adolescents, Prevention, In adults) in Japan (Intradermal)
 - 31 Oct 2018 Discontinued - Phase-III for Influenza virus infections (In children, Prevention) in Japan (Intradermal)
 - 31 Oct 2018 Discontinued - Preregistration for Influenza virus infections (Prevention) in Japan (Intradermal)